CoChat

IL-25 regulates Th17 function in autoimmune inflammation

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Interleukin (IL)-25 is a member of the IL-17 family of cytokines. However, unlike the other members of this family, IL-25 promotes T helper (Th) 2 responses. We now show that IL-25 also regulates the development of autoimmune inflammation mediated by IL-17-producing T cells. We have generated IL-25-deficient (il25-/-) mice and found that they are highly susceptible to experimental autoimmune encephalomyelitis (EAE). The accelerated disease in the il25-/- mice is associated with an increase of IL-23 in the periphery and a subsequent increase in the number of inflammatory IL-17-, IFNgamma-, and TNF-producing T cells that invade the central nervous system. Neutralization of IL-17 but not IFNgamma in il25-/- mice prevented EAE, suggesting that IL-17 is a major disease-promoting factor. IL-25 treatment at several time points during a relapse-remitting model or chronic model of EAE completely suppressed disease. IL-25 treatment induced elevated production of IL-13, which is required for suppression of Th17 responses by direct inhibition of IL-23, IL-1beta, and IL-6 expression in activated dendritic cells. Thus, IL-25 and IL-17, being members of the same cytokine family, play opposing roles in the pathogenesis of organ-specific autoimmunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20061738

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. il25−/− mice are highly susceptible to EAE. (A) Taqman PCR analysis of IL-25 mRNA levels in spinal cords from C57BL/6 WT normal and diseased versus il25-LacZ-KI normal and diseased (n = 6 mice per group). Data shown are representative of at least two experiments. ND, not detectable. (B) IL-25 mRNA expression in CNS-resident microglia. Brain leukocytes were isolated from bone marrow chimeras expressing the CD45.2 allotype on radiation-resistant host cells and the CD45.1 allotype on donor leukocytes. CD11b+CD45.2loCD45.1neg resident microglia were purified from >100 irradiation bone marrow chimeric naive or diseased (day 14) mice. Data from quantitative real-time PCR analysis for IL-25 expression were normalized to ubiquitin. (C) Clinical score (top) and percentage of incidence of disease (bottom) of C57BL/6 (WT) and il25−/− mice immunized with MOG/CFA s.c. on day 0 and PTX i.v. on days 0 and 2. The dagger indicates that by day 17, all il25−/− mice had died from EAE-associated complications. Data shown are 7–9 mice per group and are representative of at least three experiments.
Figure 1. il25−/− mice are highly susceptible to EAE. (A) Taqman PCR analysis of IL-25 mRNA levels in spinal cords from C57BL/6 WT normal and diseased versus il25-LacZ-KI normal and diseased (n = 6 mice per group). Data shown are representative of at least two experiments. ND, not detectable. (B) IL-25 mRNA expression in CNS-resident microglia. Brain leukocytes were isolated from bone marrow chimeras expressing the CD45.2 allotype on radiation-resistant host cells and the CD45.1 allotype on donor leukocytes. CD11b+CD45.2loCD45.1neg resident microglia were purified from >100 irradiation bone marrow chimeric naive or diseased (day 14) mice. Data from quantitative real-time PCR analysis for IL-25 expression were normalized to ubiquitin. (C) Clinical score (top) and percentage of incidence of disease (bottom) of C57BL/6 (WT) and il25−/− mice immunized with MOG/CFA s.c. on day 0 and PTX i.v. on days 0 and 2. The dagger indicates that by day 17, all il25−/− mice had died from EAE-associated complications. Data shown are 7–9 mice per group and are representative of at least three experiments.CC BY-NC-SA · PubMed Central
Figure 2. Increased numbers of CNS-infiltrating inflammatory Th17 cells in il25−/− mice. (A) Intracellular cytokine staining of FITC-gated CD4+ T cells isolated from the CNS of mice at day 7 after immunization (left, flow cytometric analysis; right, calculated number of cytokine-producing cells). (B) Number of cytokine-producing CD4+ cells in CNS taken at peak of disease. For A and B, cells from four mice were pooled for intracellular cytokine analysis. Data are representative of two experiments. (C) Disease score of il25−/− mice immunized with MOG/CFA (n = 4 mice per group) and treated with antibodies against IL-17 or IFNγ or with rat IgG1 control antibody. Data shown are representative of two experiments.
Figure 2. Increased numbers of CNS-infiltrating inflammatory Th17 cells in il25−/− mice. (A) Intracellular cytokine staining of FITC-gated CD4+ T cells isolated from the CNS of mice at day 7 after immunization (left, flow cytometric analysis; right, calculated number of cytokine-producing cells). (B) Number of cytokine-producing CD4+ cells in CNS taken at peak of disease. For A and B, cells from four mice were pooled for intracellular cytokine analysis. Data are representative of two experiments. (C) Disease score of il25−/− mice immunized with MOG/CFA (n = 4 mice per group) and treated with antibodies against IL-17 or IFNγ or with rat IgG1 control antibody. Data shown are representative of two experiments.CC BY-NC-SA · PubMed Central
Figure 3. Reduced Th2 cytokine production but normal regulatory T cell response in il25−/− DLN cells. (A) mRNA expression in MOG-stimulated DLN cells taken at day 7 after immunization. Expression levels are normalized to ubiquitin. n = 5. Obtained DLN samples were pooled in three different pools for mRNA processing. (B) In vitro cytokine recall response. DLN cells from MOG-immunized il25−/− and WT mice were isolated at day 7 after immunization. Cells were stimulated with MOG peptide for 3 d and then restimulated with anti-CD3/anti-CD28 for 2 additional days. Supernatants were from 24- or 72-h cultures as indicated. Data are representative of three experiments. All cytokines were measured by cytometric bead array except for IL-13 and IL-17, which were detected by ELISA as described in Materials and methods. ND, not detectable. *, P < 0.05 (unpaired two-tailed t test). (C) Generation of regulatory T cells in il25−/− and WT mice before (pooled sample of two mice per group) and 7 d after (pooled sample of four mice per group) immunization with MOG/CFA. DLN cells were stained for CD4, CD25, and Foxp3.
Figure 3. Reduced Th2 cytokine production but normal regulatory T cell response in il25−/− DLN cells. (A) mRNA expression in MOG-stimulated DLN cells taken at day 7 after immunization. Expression levels are normalized to ubiquitin. n = 5. Obtained DLN samples were pooled in three different pools for mRNA processing. (B) In vitro cytokine recall response. DLN cells from MOG-immunized il25−/− and WT mice were isolated at day 7 after immunization. Cells were stimulated with MOG peptide for 3 d and then restimulated with anti-CD3/anti-CD28 for 2 additional days. Supernatants were from 24- or 72-h cultures as indicated. Data are representative of three experiments. All cytokines were measured by cytometric bead array except for IL-13 and IL-17, which were detected by ELISA as described in Materials and methods. ND, not detectable. *, P < 0.05 (unpaired two-tailed t test). (C) Generation of regulatory T cells in il25−/− and WT mice before (pooled sample of two mice per group) and 7 d after (pooled sample of four mice per group) immunization with MOG/CFA. DLN cells were stained for CD4, CD25, and Foxp3.CC BY-NC-SA · PubMed Central
Figure 4. IL-25 inhibits the effector phase of EAE and suppresses clinical disease relapse. (A) Clinical score of SJL mice (n = 5 per group) injected with 3 × 109 particles of indicated rAdV by intracerebral ventricular injection 1 d before or 10 d after immunization. (B) Histopathological analysis of spinal cords from SJL mice at day 18 after immunization. Mice were treated with GFP-rAdV (left) or IL-25-rAdV (right) at day 1. (bottom) 10-fold magnification of boxed area in top panels. Bars, 100 μm. Results of histological analysis are summarized in Table S1 (available at http://www.jem.org/cgi/content/full/jem.20061738/DC1). (C) Clinical score of mice (n = 4–5 per group) that received 2 × 107 activated PLP-specific lymphocytes. Recipient mice were treated with 3 × 109 particles of indicated rAdV at day 0 (top) or day 3 (bottom) after PLP-cell adoptive transfer. (left) Kinetics of mean disease score; (right) maximum disease score per individual mouse during 16 d of observation. (D) Clinical score of EAE-primed mice (n = 7–10 per group) injected with 3 × 109 particles of indicated rAdV by an intracerebral ventricular route during disease remission (20 d after immunization, arrow). Mice were observed for two disease-relapse cycles. Results are representative of at least two experiments.
Figure 4. IL-25 inhibits the effector phase of EAE and suppresses clinical disease relapse. (A) Clinical score of SJL mice (n = 5 per group) injected with 3 × 109 particles of indicated rAdV by intracerebral ventricular injection 1 d before or 10 d after immunization. (B) Histopathological analysis of spinal cords from SJL mice at day 18 after immunization. Mice were treated with GFP-rAdV (left) or IL-25-rAdV (right) at day 1. (bottom) 10-fold magnification of boxed area in top panels. Bars, 100 μm. Results of histological analysis are summarized in Table S1 (available at http://www.jem.org/cgi/content/full/jem.20061738/DC1). (C) Clinical score of mice (n = 4–5 per group) that received 2 × 107 activated PLP-specific lymphocytes. Recipient mice were treated with 3 × 109 particles of indicated rAdV at day 0 (top) or day 3 (bottom) after PLP-cell adoptive transfer. (left) Kinetics of mean disease score; (right) maximum disease score per individual mouse during 16 d of observation. (D) Clinical score of EAE-primed mice (n = 7–10 per group) injected with 3 × 109 particles of indicated rAdV by an intracerebral ventricular route during disease remission (20 d after immunization, arrow). Mice were observed for two disease-relapse cycles. Results are representative of at least two experiments.CC BY-NC-SA · PubMed Central
Figure 5. IL-25 induces Th2 and suppresses Th17 independent of IFNγ. (A) Clinical score of immunized WT and il25−/− mice compared with immunized WT mice injected daily s.c. with mIL-25 protein from day 1 to the end of the experiment. Results are representative for at least four experiments with five to six mice per group. (B) Clinical score of ifng−/− (GKO) mice (n = 5 per group) injected daily with PBS or mIL-25 (s.c.) from days 1–12. Results are representative of two experiments. (C) DLN cells from MOG-immunized WT or ifng−/− mice treated with IL-25 or saline were analyzed for cytokine gene expression at day 7 after immunization (five mice per group; DLN cells were processed in three different pools for mRNA analysis). Cytokine gene expression was normalized to ubiquitin. (D) In vitro cytokine recall response. DLN cells from MOG-immunized WT mice treated with PBS or mIL-25 daily s.c. were isolated at day 7 after immunization. Cells were stimulated with MOG peptide for 3 d and restimulated with anti-CD3/anti-CD28 for 2 additional days. Cytokine levels in supernatants were measured by CBA or ELISA. Cells from individual animals were cultured separately, and data are mean cytokine levels ± SD of three to five mice per treatment group. For IFNγ detection, nine mice per treatment group are shown. Data are representative of at least two experiments. *, P < 0.05. (E) DLN cells from MOG-immunized WT and ifng−/− (GKO) mice treated with IL-25 or saline (pool of four mice per group) were stimulated in vitro with MOG for 3 d followed by incubation with IL-2 for another 2 d. Frequencies (FACS plots) and absolute numbers (bar graph) of MOG-specific IL-17–producing CD4+ cells were assessed. Data shown are representative of two experiments.
Figure 5. IL-25 induces Th2 and suppresses Th17 independent of IFNγ. (A) Clinical score of immunized WT and il25−/− mice compared with immunized WT mice injected daily s.c. with mIL-25 protein from day 1 to the end of the experiment. Results are representative for at least four experiments with five to six mice per group. (B) Clinical score of ifng−/− (GKO) mice (n = 5 per group) injected daily with PBS or mIL-25 (s.c.) from days 1–12. Results are representative of two experiments. (C) DLN cells from MOG-immunized WT or ifng−/− mice treated with IL-25 or saline were analyzed for cytokine gene expression at day 7 after immunization (five mice per group; DLN cells were processed in three different pools for mRNA analysis). Cytokine gene expression was normalized to ubiquitin. (D) In vitro cytokine recall response. DLN cells from MOG-immunized WT mice treated with PBS or mIL-25 daily s.c. were isolated at day 7 after immunization. Cells were stimulated with MOG peptide for 3 d and restimulated with anti-CD3/anti-CD28 for 2 additional days. Cytokine levels in supernatants were measured by CBA or ELISA. Cells from individual animals were cultured separately, and data are mean cytokine levels ± SD of three to five mice per treatment group. For IFNγ detection, nine mice per treatment group are shown. Data are representative of at least two experiments. *, P < 0.05. (E) DLN cells from MOG-immunized WT and ifng−/− (GKO) mice treated with IL-25 or saline (pool of four mice per group) were stimulated in vitro with MOG for 3 d followed by incubation with IL-2 for another 2 d. Frequencies (FACS plots) and absolute numbers (bar graph) of MOG-specific IL-17–producing CD4+ cells were assessed. Data shown are representative of two experiments.CC BY-NC-SA · PubMed Central
Figure 6. IL-13 is required for Th17 suppression in IL-25–mediated protection from EAE. Clinical score of il4 −/− (A), il13 −/− (B), or il4ra −/− mice (C), with five mice per group injected daily with PBS or mIL-25 (s.c.) from days 1–12. Results are representative of two experiments. (D–F) Naive T cells and LPS-activated CD11c+ DCs were obtained from DO11.10 × RAG−/− mice (pool of five mice) and incubated for 3 d with IL-23 in the presence of OVA peptide. IFNγ and IL-4 were neutralized in these cultures. (D) The effect of IL-25 addition on the number of IL-23–induced IL-17 producers was assessed by intracellular staining for IL-17. (E) IL-13 expression in these cultures was determined by LUMINEX. (F) The modulation of IL-17 protein production in IL-23–driven cultures by IL-25, IL-25 plus anti–IL-13, and IL-13 is shown in percentage of IL-23–induced IL-17 production without addition of exogenous factors (mean IL-17 production is 202.3 pg/ml, assessed by LUMINEX). Data shown are representative of at least two experiments (D and E) or pooled data from two similar experiments (F). (G) Purified MOG33-55 TCR transgenic T cells and LPS-activated CD11c+ DCs were incubated for 4 d with IL-23 in the presence of MOG peptide and neutralizing antibodies against IFNγ and IL-4. IL-17 production after incubation with IL-25, IL-25 plus anti–IL-13, and IL-13 was measured by LUMINEX. (H) DCs were purified from spleens and superficial lymph nodes and activated with LPS with or without addition of IL-13. After 24 h, mRNA expression relative to ubiquitin was measured for IL-23p19, IL-1β, and IL-6 by quantitative real-time PCR. Shown is an experiment using DCs from C57BL/6 mice representative of two C57BL/6 and two BALB/c experiments with a similar outcome (n = 3–5 mice pooled per experiment).
Figure 6. IL-13 is required for Th17 suppression in IL-25–mediated protection from EAE. Clinical score of il4 −/− (A), il13 −/− (B), or il4ra −/− mice (C), with five mice per group injected daily with PBS or mIL-25 (s.c.) from days 1–12. Results are representative of two experiments. (D–F) Naive T cells and LPS-activated CD11c+ DCs were obtained from DO11.10 × RAG−/− mice (pool of five mice) and incubated for 3 d with IL-23 in the presence of OVA peptide. IFNγ and IL-4 were neutralized in these cultures. (D) The effect of IL-25 addition on the number of IL-23–induced IL-17 producers was assessed by intracellular staining for IL-17. (E) IL-13 expression in these cultures was determined by LUMINEX. (F) The modulation of IL-17 protein production in IL-23–driven cultures by IL-25, IL-25 plus anti–IL-13, and IL-13 is shown in percentage of IL-23–induced IL-17 production without addition of exogenous factors (mean IL-17 production is 202.3 pg/ml, assessed by LUMINEX). Data shown are representative of at least two experiments (D and E) or pooled data from two similar experiments (F). (G) Purified MOG33-55 TCR transgenic T cells and LPS-activated CD11c+ DCs were incubated for 4 d with IL-23 in the presence of MOG peptide and neutralizing antibodies against IFNγ and IL-4. IL-17 production after incubation with IL-25, IL-25 plus anti–IL-13, and IL-13 was measured by LUMINEX. (H) DCs were purified from spleens and superficial lymph nodes and activated with LPS with or without addition of IL-13. After 24 h, mRNA expression relative to ubiquitin was measured for IL-23p19, IL-1β, and IL-6 by quantitative real-time PCR. Shown is an experiment using DCs from C57BL/6 mice representative of two C57BL/6 and two BALB/c experiments with a similar outcome (n = 3–5 mice pooled per experiment).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

Items 301–399 of 399

Metadata

Authors
Kleinschek, M. A., Owyang, A. M., Joyce-Shaikh, B., Langrish, C. L., Chen, Y., Gorman, D. M., Blumenschein, W. M., McClanahan, T., Brombacher, F., Hurst, S. D., Kastelein, R. A., & Cua, D. J.
Affiliations
  • 1Discovery Research
  • 2Experimental Pathology and Pharmacology, Schering-Plough Biopharma, Palo Alto, CA 94304
  • University of Cape Town (ZA)
Venue
The Journal of Experimental Medicine
Published
2007-01-02
Volume
204
Issue
1
Pages
161-170
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2118140057
Cited by
396
References
58
Citations by year
2026: 4 · 2025: 12 · 2024: 7 · 2023: 11 · 2022: 13 · 2021: 14 · 2020: 20 · 2019: 14 · 2018: 15 · 2017: 12 · 2016: 23 · 2015: 14 · 2014: 24 · 2013: 15 · 2012: 32
FWCI
16.20
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
IL-25, Th17 cells, IL-17, autoimmune encephalomyelitis, IL-23, IL-13, dendritic cells, IL-1β, interleukin-6, IL-17 family cytokines, organ-specific autoimmunity, Th2 immune response, relapsing-remitting EAE, cytokine therapy
MeSH terms
Animals, Base Sequence, Central Nervous System, DNA, Encephalomyelitis, Autoimmune, Experimental, Female, T-Lymphocytes, Helper-Inducer, Inflammation, Interferon-gamma, Interleukins, Male, Mice, Inbred C57BL, Autoimmunity, Mice, Knockout, Th2 Cells, Interleukin-17, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.